Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 21, Issue 1, 1999, Pages 47-51

  Ehrlich, A ^b   Lucker P W ^b   Wiedemann, A ^a   Sander, P ^a   Huber, R ^a   Mascher, H ^c  

^a ALTANA PHARMA AG   (Germany)

^b Prof Dr Lucker GmbH   (Germany)

^c Pharm Analyt Labor GmbH   (Austria)

Author keywords

Healthy volunteers; Intragastric pH; Omeprazole MUPS; Pantoprazole

Indexed keywords

GASTRIN; OMEPRAZOLE; PANTOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PH MEASUREMENT; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

EID: 0344958680     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1999.21.1.527018     Document Type: Article

References (25)

1. Shin, J. M., Besancon, M., Prinz, C., Simon, A., Sachs, G. Continuing development of acid pump inhibitors: Site action of pantoprazole. Aliment Pharmacol Ther 1996, 34: 51-7.
2. Müller, P., Simon, B., Khalil, H., Lühmann, R., Leucht, U., Schneider, A. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 1992, 30: 771-5.
3. Bochenek, W., Miska, D. Efficacy of pantoprazole in reflux erosive esophagitis (EE) is dose-related. Digestion 1998, 59 (Suppl. 3): 601
4. Huber, R., Hartmann, M., Bliesath, H., Lühmann, R., Steinijans, V. W., Zech, K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996, 34:7-16.
5. Meyer, U. A. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole, and pantoprazole with other drugs. Eur J Gastroenterol Heptol 1996, 8(Suppl. 1): 21-5.
6. Steinijans, V. W., Huber, R., Hartmann, M., Zech, K., Bliesath, H., Wurst, W., Radtke, H. W. Lack of pantoprazole drug interactions in man: An updated review. Int J Clin Pharmacol Ther 1996, 34: 31-50.
7. Parsons, M. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996, 8(Suppl. I): 15-20.
8. Dammann, H. G., Bethke, T., Burkhardt, F. Wolf, N., Khalil, H., Lühmann, R. Effects of pantoprazole on endocrine function in healthy male volunteers. Aliment Pharmacol Ther 1994, 8(5): 549-54.
9. Andersson, T., Cederberg, C., Heggelund, A. Lundborg, P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991, 3: 45-52.
10. Cederberg, C., Andersson, T., Skånberg, I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989, 24(Suppl. 166): 33-40.
11. Zech, K., Steinijans, V. W., Huber, R., Kolossa, N., Radtke, H. W. Pharmacokinetics and drug interactions - relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996, 34(Suppl. I): 3-6.
12. Brunner, G., Danz-Neff, H., Athmann, C., Samayoa, N. Comparison of pantoprazole (40 mg sid) versus omeprazole (40 mg sid) on intragastric pH and serum gastrin in healthy volunteers. Gastroenterology 1997, 112(Suppl. 4): A78.
13. Koop, H., Kuly, S., Flug, M., Schneider, A., Rose, K. Comparison of 24-h intragastric pH and 24-h gastrin profiles during therapy with the proton pump inhibitors pantoprazole and omeprazole. Gut 1994, 35(Suppl. 4): 1172.
14. Fitton, A., Wiseman, L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorder. Drugs 1996, 51: 460-82.
15. Londong, W. Effects of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994, 8(Suppl. 1): 39-46.
16. Hartmann, M., Theiss, U., Huber, R., Lühmann, R., Bliesath, H., Wurst, W., Lücker, P.W. Twenty-four hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996, 10: 359-66.
17. Witzel, L., Gutz, H., Hüttemann, W., Schepp, W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995, 9: 19-24.
18. Timmer, W., Wehling, M., Theiss, U. 24-hour recording of intragastric pH in clinical trials: Preconditions, methodology, and standardization strategies. J Clin Pharmacol 1997, 37: 34-9.
19. +-ATPase inhibitor (BY1023/SK&F96022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up. J Chromatog 1990, 529: 389-401.
20. Sauter, R., Steinijans, V.W., Diletti, E., Böhm, A., Schultz, H.U. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992, 30: 233-56.
21. Hollander, M., Wolfe, D. A. Nonparametrical Statistical Methods. Wiley & Sons: New York 1972.
22. Simon, B., Müller, P., Marinis, E., Lühmann, R., Huber, R., Hartmann, M., Wurst, W. Effect of repeated oral administration of BY1023/SK&F96022 - a new substituted benzimidazole derivative -on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990, 4: 373-9.
23. Andersson, T., Andrén, K., Cederberg, C., Lagerström, P.-O., Lundborg, P., Skånberg, I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990, 29: 557-63.
24. Andersson, T., Andrén, K., Cederberg, C., Heggelund, A., Lundborg, P., Röhss, K. Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seventh days of treatment. Drug Invest 1990, 2(3): 184-8.
25. Andersson, T., Bergstrand, R., Cederberg, C. Influence of acid secretory status on absorption of omeprazole from enteric coated granules. Br J Clin Pharmacol 1991, 31: 275-8.